Posted by duane on February 6, 2022 at 3:39 pm

    Findings  In this multicenter, propensity score–matched cohort study of 324 patients with ALS, long-term intravenous edaravone treatment was feasible and was mainly well tolerated. However, disease progression rates, time to noninvasive ventilation, and survival probability did not significantly differ from matched patients with ALS receiving only standard therapy.

    Meaning  These findings show that reatment with long-term intravenous edaravone in addition to standard therapy for patients with ALS is feasible and relatively safe but may not provide a clinically relevant benefit.


    <span class=”meta-citation-journal-name”>JAMA Neurol. </span><span class=”meta-citation”>Published online January 10, 2022. doi:10.1001/jamaneurol.2021.4893</span>

    duane replied 1 year, 7 months ago 0 Member · 0 Replies
  • 0 Replies

Sorry, there were no replies found.

Log in to reply.